Why the study?
Cisplatin-based chemotherapy is standard treatment for metastatic testicular cancer, but its effects on physical fitness and body composition during and after treatment needed evaluation.
Does cisplatin-based chemotherapy reduce physical fitness and alter body composition in men with metastatic testicular cancer?
Does cisplatin-based chemotherapy reduce physical fitness and alter body composition in men with metastatic testicular cancer?
Cisplatin-based chemotherapy causes significant but transient reductions in cardiorespiratory fitness, muscle strength, and lean body mass in patients with metastatic testicular cancer.
Should not yet change CBCT practice; leaves open whether exercise can prevent the fitness nadir.
Introduction : Cisplatin-based chemotherapy (CBCT) is standard treatment for most men with metastatic testicular cancer (TC). The main objective was to evaluate changes in physical fitness and body composition from before to immediately after CBCT and three months after completion of CBCT. Patients and materials: The assessments included cardiorespiratory fitness (peak oxygen uptake [VO 2 peak]), muscle strength (one repetition maximum [1RM]) and muscular endurance in leg- and chest press, body composition (dual-energy X-ray absorptiometry), physical activity (PA) levels, and patient-reported outcomes (functional scales, global quality of life [QoL], mental health and fatigue). Twenty-eight patients were included, most with low-volume metastatic disease and all within the good prognosis risk group. Results: From before the start of CBCT to immediately after the last CBCT cycle, there were significant reductions in VO 2 peak by 24% (p<.001) , 1RM leg press by 8% (p=.004), 1RM chest press by 17% (p=.001), chest press endurance by 22% (p=.005), total lean body mass by 2.2 kg (p<.001), PA level, physical-, role-, cognitive- and social functioning, and QoL; and significant increases in total and physical fatigue and symptoms of depression. There was a good correlation between reductions in VO 2 peak and QoL during CBCT (r=.54, p=.016), whereas no correlation between reductions in VO 2 peak and PA levels. Twelve weeks after CBCT, all variables had returned to baseline values except for PA levels and physical functioning. Conclusion: TC patients should be prepared for reductions in physical fitness and QoL during CBCT. The reduction in cardiovascular fitness is possibly independent of the PA level. Microabstract First comprehensive report on changes in cardiorespiratory fitness, muscle strength and muscular endurance in lower and upper body, body composition, patient reported outcomes and physical activity level, in twenty-eight included testicular cancer patients, during cisplatin-based chemotherapy (CBCT) and after three months of follow-up. Reductions were seen in physical fitness and quality of life during CBCT but were restored at follow-up.
No takes yet. Share an insight, caveat, or question.
Negaard et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: